泛亚洲改编版ESMO临床实践指南：早期和局部晚期非小细胞肺癌患者的诊断、治疗与随访。
完整摘要 · 中文译文
欧洲肿瘤内科学会（ESMO）关于早期和局部晚期非小细胞肺癌（NSCLC）患者的诊断、治疗和随访临床实践指南于2025年8月发布，并于2025年11月根据先前建立的标准方法进行改编，以制定泛亚洲改编版ESMO共识指南，用于亚洲早期和局部晚期NSCLC患者的管理。本文所呈现的改编指南代表了由亚洲专家小组就早期和局部晚期NSCLC患者的治疗所达成的共识意见，该专家小组代表了中国（中国临床肿瘤学会）、印度尼西亚（印度尼西亚血液学和医学肿瘤学会）、印度（印度医学和儿科肿瘤学会）、日本（日本医学肿瘤学会（JSMO））、韩国（韩国医学肿瘤学会）、马来西亚（马来西亚肿瘤学会）、菲律宾（菲律宾医学肿瘤学会）、新加坡（新加坡肿瘤学会）、台湾（台湾肿瘤学会）和泰国（泰国临床肿瘤学会）的肿瘤学会，由ESMO和JSMO协调。投票基于科学证据，独立于亚洲不同地区当前的治疗实践、药物可及性限制和报销决策。后者在文章中另行讨论。其目的是为优化和统一亚洲各地早期和局部晚期NSCLC患者的管理提供指导。 亚洲不同国家的情况，基于西方和亚洲试验所提供的证据。文中关注到不同地区在药物批准和报销策略上存在的差异。
完整摘要 · 英文原文
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early and locally advanced non-small-cell lung cancer (NSCLC) were published in August 2025 and were adapted in November 2025 according to previously established standard methodology to produce the Pan-Asian adapted ESMO consensus guidelines for the management of Asian patients with early and locally advanced NSCLC. The adapted guidelines presented in this article represent the consensus opinions reached by a panel of Asian experts on the treatment of patients with early and locally advanced NSCLC representing the oncological societies of China (Chinese Society of Clinical Oncology), Indonesia (Indonesian Society of Hematology and Medical Oncology), India (Indian Society of Medical and Paediatric Oncology), Japan [Japanese Society of Medical Oncology (JSMO)], South Korea (Korean Society of Medical Oncology), Malaysia (Malaysian Oncological Society), the Philippines (Philippine Society of Medical Oncology), Singapore (Singapore Society of Oncology), Taiwan (Taiwan Oncology Society) and Thailand (Thai Society of Clinical Oncology), coordinated by ESMO and JSMO. The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different regions of Asia. The latter are discussed separately in the article. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with early and locally advanced NSCLC across the different countries of Asia, drawing on the evidence provided by both Western and Asian trials. Attention is drawn to the disparity in the drug approvals and reimbursement strategies among the different regions.